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osting by EAbstract Background and objective: The purpose of this study was to evaluate the once daily
dosing (ODD) program in critically ill Egyptian patients compared to individualized multiple daily
dosing (MDD) in terms of clinical and bacteriological efﬁcacy. In addition, the incidence of
nephrotoxicity associated with both regimens in this speciﬁc group of patients was assessed.
Methods: Fifty-two patients with suspected or conﬁrmed bacterial infections admitted to the
Critical Care Medicine Department, Kasr El-Aini-Cairo University Hospitals comprised the study
population. The amikacin group (30 patients) was sub-divided into 14 patients receiving amikacin
ODD (1 g i.v.) and 16 patients receiving amikacin in MDD (500 mg i.v./dose). The gentamicin
group (22 patients) was sub-divided into 10 patients receiving the drug ODD (240 mg i.v.) and
12 patients receiving gentamicin MDD (80 mg i.v./dose). Amikacin or gentamicin serum levels were
determined by the enzyme multiplied immunoassay technique using Emit 2000. MDD regimen was
adjusted based on the individual pharmacokinetic parameters using the Sawchuk–Zaske method.
Results: There was no signiﬁcant difference between the two dosing regimens with regard to clin-
ical and antibacterial efﬁcacy or incidence of nephrotoxicity of both gentamicin and amikacin5807504.
om (N.S. Bazan).
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10 A. Abdel-Bari et al.groups. In the ODD regimen, duration of treatment had no effect on increasing incidence of neph-
rotoxicity unlike the individualized MDD regimen. No dose adjustments were needed in the once
daily dosing regimen since trough concentrations have never been above toxic level.
Conclusions: The study showed that the ODD regimen is preferred in critically ill patients to indi-
vidualized MDD as shown by comparable efﬁcacy, nephrotoxicity and lesser need for therapeutic
drug monitoring and frequent dose adjustments required in the individualized MDD regimen.
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Aminoglycosides are extremely active antimicrobial agents
(Gilbert, 1991) and currently play a pivotal role in the manage-
ment of serious infections (Durante-Mangoni et al., 2008;
Trenika et al., 2005). They have been traditionally adminis-
tered every 8–12 h. Although this dosing schedule has been
shown to be effective in eradicating various strains of bacteria,
it has been associated with dose limiting toxicities, mainly
nephrotoxicity and ototoxicity (Maglio et al., 2002). However,
the high efﬁcacy and rare emergence of resistance to aminogly-
cosides made the attention to the correct use, monitoring of
aminoglycosides and understanding of aminoglycosides, phar-
macokinetics so as to ensure the achievement of therapeutic
serum levels while avoiding toxic concentrations. Substantial
inter- and intra-patient variations occur in the distribution vol-
ume and the elimination rate constant of aminoglycosides,
which determine dosage requirements. Hence, the pharmacoki-
netic dosing method has been recommended as the most desir-
able dosing method (Zaske et al., 1982). In addition, the
emergence of once daily aminoglycoside administration can
be attributed to several pharmacodynamic characteristics of
the drug class, including: concentration dependent killing,
the post-antibiotic effect, a diminished propensity for adaptive
resistance, and reduced toxicity (Freeman et al., 1997; Klaster-
sky et al., 1974; Ward and Theiler, 2008).
2. Patients and methods
2.1. Patients’ characteristics
Fifty-two patients (26 males and 26 females) with mean age
(42.4 ± 18.4, range 21–80) with suspected or conﬁrmed bacte-
rial infections for which an aminoglycoside (amikacin or gen-
tamicin) was indicated were included in the study. Apache II
score was applied for all patients before and after stopping
aminoglycoside therapy. The data with respect to infections
for which treatment is indicated, coexistent disease, and con-
comitantly prescribed drugs were obtained. All patients were
with creatinine clearance of 30 ml/min or more except one pa-
tient had creatinine clearance of 18.3 ml/min, they had no clin-
ically apparent hearing loss or vestibular disease. Twenty-two
patients received gentamicin (80 mg/ampoule) by intravenous
route. They were divided into two subgroups, the ﬁrst sub-
group comprising 10 patients, received 240 mg gentamicin
once daily and the second subgroup of 12 patients received
80 mg gentamicin every 8 h. Thirty patients received amikacin
(500 mg/vial) by intravenous route. They were also divided
into two subgroups, the ﬁrst subgroup comprised 14 patients
who received 1000 mg amikacin once daily and the second sub-
group comprised 16 patients, 14 of them received 500 mg ami-kacin 12 hourly and 2 received 500 mg 8 hourly. All patients
whether taking gentamicin or amikacin also received other
antimicrobial agents as prescribed by their physicians. As some
patients in the two treatment subgroups whether in amikacin
group or gentamicin group, had multiple infections, some
had single infections and few received amikacin or gentamicin
for prevention of infections, this study dealt with each infec-
tion whether conﬁrmed or suspected separately so that clinical
and microbiological cure of each conﬁrmed or suspected infec-
tion could be evaluated. The need for informed consent form
was waived because all invasive procedures used were already
undertaken for clinical purpose.
2.2. Serum aminoglycoside level determination
The decision to start aminoglycoside therapy either once or
multiple daily dosing and the choice between gentamicin and
amikacin were made by the attending physician according to
clinical status independent of the study. Following clinical
evaluation and routine laboratory tests all patients received
the antibiotic chosen with periodic measurement of serum lev-
els of either amikacin or gentamicin. The appropriate thera-
peutic serum levels for multiple daily dosing were 5–10 lg/ml
for gentamicin peak, 0.5 to <2 lg/ml for gentamicin trough,
and 15–35 lg/ml for amikacin peak, 5–10 lg/ml for amikacin
trough (Schentagjj, 1980; Zaske, 1986). Serum aminoglycoside
level determination was determined using enzyme multiplied
immunoassay technique (EMIT) using the Vitalab VIVA ana-
lyzer (Syva Company, Dade Behring Inc., USA) (Mendu et al.,
2007; Nishihara, 1995). The sampling intervals include; 30 min
after end of infusion of the third dose, half of the dosing inter-
val between the third and fourth dose, and 15–30 min just be-
fore the fourth dose (Dorman et al., 1998; Huber, 1996; Jikoo
et al., 1996). These intervals were chosen to ensure that the
drug had reached steady state concentration.
2.3. Pharmacokinetic parameters and dose individualization
Both drugs were given with 100 ml saline over 1 h, and amino-
glycoside dosing was individualized for the conventional dosing
group if trough concentration exceeded the toxic level. Dataki-
netics program (developed by MDK, Inc., Baldwin, MO,
USA, and marketed by American Society of Health-
SystemPharmacists [ASHP])was used to calculate the estimated
pharmacokinetic parameters, calculated pharmacokinetic
parameters according to serum drug concentrations, and for
individualizing pharmacokinetic dosing (Erdman et al., 1991;
Goldman and Fuller, 1993; Sawchuk and Zaske, 1976). No dose
adjustments were needed in the once daily dosing regimen since
trough concentrations have never been above toxic level in both
aminoglycosides.
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Samples from the different sites of infection; blood, swab, spu-
tum, urine and/or peritoneal effusion were taken and cultured
for microorganism identiﬁcation, before and after treatment
and the minimum inhibitory concentration (MIC) was calcu-
lated when possible. Antibiotic sensitivity, identiﬁcation of
isolated strains and MIC was determined by Microscan appa-
ratus (Dade Behring Inc., USA). The bacteria showing an
MIC for gentamicin of less than or equal to four and of less
than or equal to 16 for amikacin were considered sensitive.
2.5. Evaluation of clinical and microbiological efﬁcacy
A clinical cure was deﬁned as clinical improvement of patients
with resolution of symptoms of infection, restoration of nor-
mal body temperature (37.5 C) for at least 48 h and normali-
zation of leucocyte count. In case of multiple infections each
infection was evaluated alone in terms of clinical improvement
with resolution of symptoms of infection in the relevant organ.
In case of patients with suspected bacterial infection where the
antibiotic was taken prophylactically, the efﬁcacy was assessed
on the basis of successful prevention of suspected infection. A
bacteriological cure was deﬁned as favourable if post-therapy
culture was negative or no specimens for follow up culture
were available and unfavourable if post-therapy culture was
positive for the same microorganism or for a different organ-
ism with clinical signs of infection, or resistance to gentami-
cin/amikacin developed. The bacteriological efﬁcacy was
considered indeterminate if no organism was cultured at the
start of therapy or patient died before completing therapy.
2.6. Evaluation of nephrotoxicity
Nephrotoxicity was deﬁned as an increase in serum creatinine
of P0.5 mg/dl at any time during treatment or up to 1 week
after stopping treatment (Jikoo et al., 1996). Patients who
had been treated with amphotericin B, frusemide over
160 mg daily or vancomycin were not evaluable for toxicity.
2.7. Statistical analysis
Data were collected on special format, veriﬁed and then coded
when needed prior to analysis. All continuous data were ex-
pressed as mean ± SD, categorical data were expressed as fre-
quency in tables. For comparative purposes between groups inTable 1 Baseline characteristics of amikacin and gentamicin group
Patient parameter Dosing regimen of amikacin P
ODD (n= 14) MDD (n= 16)
Mean ± SD Mean ± SD
Age (years) 46.8 ± 21.7 43.75 ± 17.54 0
Weight (kg) 62.8 ± 8.6 66 ± 12.12 0
Height (cm) 165.85 ± 11.31 166.7 ± 11.9 0
SCr (mg%) 1.01 ± 0.47 1.16 ± 0.81 0
CrCl (ml/min) 93.73 ± 51.92 92.14 ± 48.74 0
Apache II score 16.21 ± 6.62 16.7 ± 6.5 0
ODD: Once daily dosing; MDD: multiple daily dosing; CrCl: creatinine
* P-value using Mann–Whitney test.all continuous data, paired and unpaired t-test were per-
formed. When the mean values were violated Mann–Whitney
test or Wilcoxon signed ranks test was performed to assess
the difference between two groups. Chi-square test was used
for assessing association in categorical data. P-value < 0.05
was considered signiﬁcant, i.e., 95% conﬁdence interval was
used. All analysis was done using SPSS version 12 and graph-
ics utilizing MS Excel.3. Results
3.1. Patients
Fifty-two Egyptian patients were enrolled in the study. All
were admitted to the Critical Care Medicine Department,
Cairo University Hospitals and all completed the study.
Patients in the once daily dosing (ODD) and multiple daily
dosing (MDD) subgroups in either the amikacin or gentamicin
groups were comparable with respect to age, weight, height,
kidney function tests and Apache II Score (Table 1).
Moreover, a statistically non-signiﬁcant difference in sex distri-
bution between the two subgroups was obtained.
3.2. Clinical and microbiological efﬁcacy
Some patients in the two treatment subgroups of either amika-
cin or gentamicin groups had multiple infections, some had
single infections and few received amikacin or gentamicin for
prevention of infection, so each infection whether conﬁrmed
or suspected was dealt with separately so that clinical and
microbiological cure could be evaluated. A statistically non-
signiﬁcant difference was obtained concerning different types
of infections in the two treatment subgroups of either amikacin
or gentamicin (Table 2).
The statistical analysis of the data showed that there was no
statistically signiﬁcant difference between the two dosing
regimens concerning clinical and antibacterial efﬁcacy of both
gentamicin and amikacin groups. In amikacin ODD subgroup
13 of 24 (54.2%) infections achieved favourable clinical re-
sponse versus 11 of 33 infections (33.3%) in MDD subgroup.
On the other hand, in the gentamicin ODD subgroup ﬁve of 15
infections (33.3%) achieved favourable clinical response versus
eight of 18 infections (44.4%) in the MDD subgroup (Table 3).
In the amikacin group, 36 infections were eligible for micro-
biological evaluation, 16 in ODD subgroup and 20 in MDD
subgroup. Out of 16 infections showing microbiological cure,s.
-value Dosing regimen of gentamicin P-value
ODD (n= 10) MDD (n= 12)
Mean ± SD Mean ± SD
.675 35.2 ± 10.07 41.58 ± 21.08 0.366
.412 63.98 ± 7.25 60.69 ± 8.74 0.355
.847 168 ± 8.23 164.25 ± 8.28 0.302
.677* 1.1 ± 0.56 0.93 ± 0.25 0.398
.967 92.4 ± 37.9 87.06 ± 39.95 0.753
.845 14.1 ± 7.4 10.8 ± 5.85 0.26
clearance; SCr: serum creatinine. Independent samples t-test.
Table 2 Types of infection in the two dosing regimens of amikacin and gentamicin groups.
Chest
infection
Abdominal
infection
Urinary
tract infection
Skin tissue
infection
Bacteremia Suspected
bacterial infection
Infective
endocarditis
P-value
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
ODD (A) 8 (33.3%) 5 (20.8%) 5 (20.8%) 3 (12.5%) 2 (8.3%) 1 (4.2%) – 0.849
MDD (A) 11 (33.3%) 5 (15.2%) 4 (12.1%) 5 (15.2%) 5 (15.2%) 3 (9.1%) –
Total 19 (33.3%) 10 (17.5%) 9 (15.8%) 8 (14%) 7 (12.3%) 4 (7%) –
ODD (G) 4 (26.7%) 1 (6.7%) 3 (20%) – 3 (20%) 2 (13.3%) 2 (13.3%) 0.397
MDD (G) 6 (33.3%) 3 (16.7%) 1 (5.6%) 2 (11.1%) 1 (5.6%) 3 (16.7%) 2 (11.1%)
Total 10 (30.3%) 4 (12.1%) 4 (12.1% 2 (6.1%) 4 (12.1%) 5 (15.2%) 4 (12.1%)
ODD: Once daily dosing; MDD: multiple daily dosing; A: amikacin; G: gentamicin. Chi-square test.
Table 3 Clinical response in the two dosing subgroups of amikacin and gentamicin.
Parameter Dosing regimen P-value
ODD MDD
No. (%) No. (%)
Clinical cure (A)
Yes 13 (54.2%) 11 (45.8%) 0.116
No 11 (33.3%) 22 (66.7%)
Clinical cure (G)
Yes 5 (33.3%) 8 (44.4%) 0.515
No 10 (66.7%) 10 (55.6%)
ODD: Once daily dosing; MDD: multiple daily dosing; A: amikacin; G: gentamicin. Chi-square test.
12 A. Abdel-Bari et al.nine infections (56.3%) belonged to ODD subgroup and seven
(43.8%) belonged to MDD subgroup (P-value = 0.202). On
the other hand, in the gentamicin group 13 infections were eli-
gible for microbiological evaluation, 10 in ODD subgroup and
three in MDD subgroup. In ODD subgroup (20%) showed
microbiological cure versus (66.7%) in the MDD subgroup.
klebsiellapneumonia, Pseudomonas aeruginosa and Enterobacter
cloacae were the most prominent microorganisms cultured
from the different sites of infections in the two dosing regimens
in the amikacin group, whereas in the gentamicin group
Klebsiella pneumonia and Staphylococcus species were the most
prominent microorganisms cultured from the different sites of
infections in the ODD regimen versus Acintobacter baumanni/Table 4 Microorganisms cultured in the two dosing regimens of am
Microorganism ODD (A)
No. (%)
Klebsiella pneumonia 5 (45.5%)
Pseudomonas aeruginosa 4 (66.7%)
Enterococcus faecium (+) –
Staphylococcus aureus (+) –
Acintobacter baumanni/haemolyticus 1 (50%)
Enterobacter cloacae 3 (30%)
Escherichia coli 1 (25%)
Pasteurella aerogenes –
Chromobacterium violecum –
Proteus species 2 (100%)
Ralstonia picketti –
Staphylococcus species 1 (33.3%)
Total 17 (42.5%)
ODD: Once daily dosing; MDD: multiple daily dosing; A: amikacin; G:haemolyticus and Proteus species in the MDD regimen
(Table 4).
3.3. Nephrotoxicity
There was a statistically non-signiﬁcant difference between
both treatment subgroups in the amikacin and gentamicin
groups combined (P-value > 0.05). Four out of 23 patients
(17.4%) in ODD subgroup versus four patients out of 26
(15.4%) in MDD subgroup suffered from nephrotoxicity.
There were no statistically signiﬁcant difference in age between
patients who had a decrease in renal function (n= 4 in ODD
and n= 4 in MDD) and those who did not (n= 19 in ODDikacin and gentamicin groups.
MDD (A) ODD (G) MDD (G)
No. (%) No. (%) No. (%)
6 (54.5%) 3 (75%) 1 (25%)
2 (33.3%) 1 (50%) 1 (50%)
1 (100%) – –
– 1 (50%) 1 (50%)
1 (50%) – 2 (100%)
7 (70%) – 1 (100%)
3 (75%) 1 (100%) –
– 1 (100%) –
1 (100%) – –
– – 2 (100%)
– 1 (100%) –
2 (66.7%) 2 (66.7%) 1 (33.3%)
23 (57.5%) 10 (52.6%) 9 (47.4%)
gentamicin.
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imens [50.75 ± 19.1 years versus 40.79 ± 18.5 years and
47 ± 22.3 years versus 41.23 ± 18.07 years, P-value = 0.343,
0.576, respectively]. In addition, duration of treatment in the
ODD regimen had no effect on probability of nephrotoxicity
occurence [5 ± 0.816 days versus 10.47 ± 6.65 days, respec-
tively, P-value = 0.06]. On the contrary, duration of treatment
in the MDD regimen was statistically signiﬁcantly higher in
patients who had nephrotoxicity than those who did not
[8.75 ± 3.3 days versus 5.73 ± 2.03 days, respectively,
P-value = 0.02]. All other factors such as Apache II score, ini-
tial creatinine clearance, sex and obesity had no effect on
increasing incidence of nephrotoxicity. In the amikacin group,
the mean peak level and AUC at steady state were statistically
non-signiﬁcant in patients who showed evidence of nephrotox-
icity (n= 5) and those who did not (n= 25) [45.2 ± 17.06 lg/
ml and 443.9 ± 352.7 mg h/l versus 33.3 ± 16.5 lg/ml and
220.7 ± 109.6 mg h/l, P-value = 0.153 and 0.254, respec-
tively]. The mean steady state trough level was statistically
non-signiﬁcant in patients showing laboratory evidence of
nephrotoxicity than those who did not [12.2 ± 13.9 lg/ml ver-
sus 4.7 ± 6 lg/ml, P-value = 0.148].
Similarly, in the gentamicin group, the mean peak concen-
tration and AUC at steady state were comparable in patients
who suffered nephrotoxicity (n= 3) and those who did not
(n= 16) [9.67 ± 8.95 lg/ml and 86.07 ± 107.9 mg h/l versus
9.9 ± 6.22 lg/ml and 71.26 ± 70.3 mg h/l, P-value = 0.737
and 0.737, respectively]. Also, the mean steady state trough le-
vel was statistically non-signiﬁcantly higher in patients show-Table 5 Relation between the time of administration of once daily
Nephrotoxicity Time of administration of once daily dosing
Other time Rest period (
No. (%) No. (%)
Yes 7 (100%) 0 (0%)
No 18 (60%) 12 (40%)
Total 25 (67.6%) 12 (32.4%)
Signiﬁcant difference at P< 0.05 using Chi-square test.
Table 6 Therapeutic drug monitoring parameters at steady state of
Pharmacokinetic parameter Dosing regimen
ODD (n= 14)
Mean ± SD
Peak level (lg/ml) (A) 45.11 ± 17.03 (n= 14
Trough level (lg/ml) (A) 4.9 ± 9.3 (n= 14)
AUC (mg h/l) (A) 350.85 ± 216.3 (n= 1
Serum creatinine (mg%) (A) 0.8 ± 0.33 (n= 14)
Creatinine clearance (ml/min) (A) 122.21 ± 82.7 (n= 14
Peak level (lg/ml) (G) 15.7 ± 6.44 (n= 10)
Trough level (lg/ml) (G) 1.2 ± 1.64 (n= 10)
AUC (mg h/l) (G) 126.86 ± 75.03 (n= 1
Serum creatinine (mg%) (G) 0.95 ± 0.33 (n= 10)
Creatinine clearance (ml/min) (G) 100.4 ± 39.4 (n= 10)
ODD: Once daily dosing; MDD: multiple daily dosing; BP: blood pressu
gentamicin. Independent samples t-test.
* P-value using Mann–Whitney test.ing laboratory evidence of nephrotoxicity than those who
did not [2.07 ± 1.01 lg/ml versus 1.4 ± 1.4 lg/ml,
P-value = 0.238].
3.3.1. Effect of time of administration of aminoglycosides’ ODD
on nephrotoxicity
The time of administering once daily aminoglycosides at the
rest period had no impact on nephrotoxicity of aminoglyco-
sides (P-value > 0.05) (Table 5).
3.4. Therapeutic drug monitoring parameters at steady state
In the amikacin group the mean steady state of peak concen-
trations of amikacin were statistically signiﬁcantly higher while
that of trough concentrations were statistically signiﬁcantly
lower in the ODD subgroup than in the MDD subgroup
[45.11 ± 17.03 lg/ml versus 26.7 ± 11.45 lg/ml and
4.9 ± 9.3 lg/ml versus 7.6 ± 6.65 lg/ml with P-value = 0.001
and 0.034, respectively]. Moreover, a highly statistical signiﬁ-
cant variability was evident in the mean area under the curve
in the ODD subgroup compared to the MDD subgroup
[350.85 ± 216.3 mg h/l versus 176.6 ± 103 mg h/l, respec-
tively, P-value = 0.005].
Finally, the mean serum creatinine and creatinine clearance
at the steady state were comparable in the two subgroups
[0.8 ± 0.33 mg%, 122.21 ± 82.7 ml/min in the ODD sub-
group versus 1.04 ± 0.84 mg%, 109.2 ± 66.25 ml/min in the
MDD subgroup, respectively, P-value > 0.05]. However in
the gentamicin group the mean steady state of the peakaminoglycosides and nephrotoxicity.
of aminoglycosides Total P-value
midnight to 7:30 am)
7 0.072
30
37
amikacin group.
P-value
MDD (n= 16)
Mean ± SD
) 26.7 ± 11.45 (n= 16) 0.001
7.6 ± 6.65 (n= 16) 0.034*
4) 163.33 ± 99.93 (n= 16) 0.001*
1.04 ± 0.84 (n= 16) 0.49*
) 109.2 ± 66.25 (n= 16) 0.868*
5.27 ± 2.3 (n= 12) 0.001
1.5 ± 1.04 (n= 12) 0.221
0) 24.91 ± 11.24 (n= 12) 0.0001*
0.94 ± 0.3 (n= 12) 0.951
90.42 ± 47.83 (n= 12) 0.604
re; AUC: area under the concentration time curve; A: amikacin; G:
14 A. Abdel-Bari et al.concentrations of gentamicin and the mean area under the
curve were statistically signiﬁcantly higher in the ODD sub-
group than in the MDD subgroup [15.7 ± 6.44 lg/ml versus
5.27 ± 2.3 lg/ml and 126.86 ± 75.03 mg h/l versus 24.91 ±
11.24 mg h/l, P-value = 0.001 and 0.0001, respectively]. No
statistical signiﬁcant variability was evident between the mean
steady state trough levels of the ODD and MDD subgroups
[1.2 ± 1.64 lg/ml versus 1.5 ± 1.04 lg/ml, respectively,
P-value > 0.05]. Finally, the mean serum creatinine and creat-
inine clearance at steady state were comparable in the two sub-
groups [0.95 ± 0.33 mg%, 100.4 ± 39.4 ml/min in the ODD
subgroup versus 0.94 ± 0.3 mg%, 90.42 ± 47.83 ml/min in
the MDD subgroup, respectively, P-value > 0.05] (Table 6).
3.5. The patients’ period of hospitalization and treatment
duration
Fourteen out of 30 patients (46.7%) received once daily amika-
cin versus 16 (53.3%) received multiple daily amikacin.
Whereas, 10 out of 22 patients (45.5%) received gentamicin
once daily versus 12 out of 22 patients (54.5%) received genta-
micin multiple daily. In the amikacin group, the mean length
of stay in the hospital in the ODD (n= 14) and MDD
(n= 16) subgroups, were 26.85 ± 26 days versus 23.62 ±
17.41 days, respectively (P-value = 0.868). Also, the mean
duration of treatment was comparable in the ODD and the
MDD subgroups (10.42 ± 7.83 days versus 6.1 ± 2.33 days,
respectively, P-value = 0.223). Similarly, in the gentamicin
group, the mean length of stay in the hospital in the ODD
and MDD subgroups were 20.5 ± 21.5 days versus
15.33 ± 11.9 days, respectively (P-value = 0.674) and the
mean duration of treatment was comparable in the ODD
and the MDD subgroups (7.9 ± 2.9 days versus 6.25 ±
2.53 days, respectively, P-value = 0.168). Out of 14 patients
in the ODD subgroup, only one patient (7.1%) died versus
three (18.8%) out of 16 patients in the MDD subgroup in case
of Amikacin. In the gentamicin group, out of 10 patients in the
ODD subgroup, only one (10%) died versus two (16.7%) out
of 12 patients in the MDD subgroup.
3.6. Factors affecting clinical efﬁcacy
In the amikacin group it was found that in the ODD or MDD
subgroups, the mean steady state of the peak or trough con-
centrations of clinically cured infections were comparable with
those which were not cured [48.12 ± 18.36 lg/ml versus
41.65 ± 10.24 lg/ml and 1.73 ± 1.76 lg/ml versus 7.1 ±
14.2 lg/ml for the ODD regimen, respectively, and 26.03 ±
11.6 lg/ml versus 27.32 ± 12.9 lg/ml and 7.5 ± 5.7 lg/ml ver-
sus 9.5 ± 8.04 lg/ml for the MDD regimen, respectively,
P-value > 0.05]. Other factors including obesity, sex, age
and duration of treatment had no impact on clinical efﬁcacy
on either regimens in both the amikacin and gentamicin
groups. However, in the gentamicin group it was found that
in the ODD or MDD subgroups, the mean steady state of
the peak concentrations of clinically cured infections were
comparable with those which were not cured [13.24 ±
7.09 lg/ml versus 16.58 ± 4.98 lg/ml for ODD regimen,
respectively, and 6.46 ± 2.45 lg/ml versus 4.67 ± 1.66 lg/ml
for the MDD regimen, respectively, P-value > 0.05]. On the
other hand, in the ODD regimen, the mean of the trough con-
centrations was statistically signiﬁcantly higher in infectionswhich were clinically not cured compared to clinically cured
infections (2.48 ± 1.96 lg/ml versus 0.36 ± 0.6 lg/ml, respec-
tively, P-value = 0.0291), while in MDD regimen the mean
trough concentrations of clinically cured infections were com-
parable with those not cured [1.62 ± 0.96 lg/ml versus 1.42 ±
0.93 lg/ml, respectively, P-value > 0.05]. Other factors includ-
ing obesity, sex, age and duration of treatment had no impact
on clinical efﬁcacy on either regimens in both the amikacin and
gentamicin groups.4. Discussion
The present study aimed at evaluating the once daily dosage
program of amikacin and gentamicin in critically ill Egyptian
patients compared to individualized multiple daily dosing in
terms of clinical and bacteriological efﬁcacy. In addition,
assessing the incidence of nephrotoxicity associated with both
regimens in this speciﬁc group of patients. The study also eval-
uated the effect of different patient characteristics which may
affect clinical efﬁcacy, bacteriological efﬁcacy and nephrotox-
icity. The obtained data show that the mean peak serum con-
centrations and the mean AUC at steady state in the ODD
subgroup were statistically signiﬁcantly higher than MDD sub-
group for both gentamicin and amikacin groups. On the other
hand, the mean steady state of the trough concentrations were
statistically signiﬁcantly lower in the ODD subgroup in amika-
cin group (P-value = 0.034), but statistically insigniﬁcantly
lower in the gentamicin group (P-value > 0.05), possibly due
to the small number of patients. The previously mentioned re-
sults are in accordance with those obtained by Prins et al.
(1993) who studied once versus thrice daily gentamicin dosing
in patients with serious infections, Raz et al. (1995) who stud-
ied intravenous administration of gentamicin once daily versus
thrice daily in adults, and Jikoo et al. (1996) who compared
once daily versus pharmacokinetic dosing of gentamicin or
tobramycin in elderly male patients. The previously mentioned
three studies reported that the mean trough levels of gentami-
cin were lower and the mean peak levels were higher in the
ODD subgroup. Moreover, Begg et al. (1995) and Prins
et al. (1993) reported that the AUC of the ODD group was
possibly much larger than the respective AUC of the conven-
tional dose of gentamicin and amikacin, respectively. In addi-
tion, Maller et al. (1988) studied amikacin given once versus
twice daily in serious infections and reported that the adminis-
tration of a single dose/24 h of amikacin yielded much high
peak concentrations than the same total dose when divided
and administered twice daily. The signiﬁcant positive correla-
tion between the trough concentration and AUC at the steady
state in either the ODD or the MDD subgroups or in both reg-
imens combined in either amikacin or gentamicin, is in agree-
ment with what was reported by Gilbert (1991) who stated that
the higher the trough concentrations the greater the area under
the time–concentration curve.
The statistical analysis of the data showed that there was no
statistically signiﬁcant difference between the two dosing regi-
mens concerning clinical and antibacterial efﬁcacy of both gen-
tamicin and amikacin groups, similar to that reported by Jikoo
et al. (1996) that a statistically non-signiﬁcant difference was
found between the ODD and pharmacokinetic dosing sub-
groups of gentamicin in terms of clinical and bacteriological
efﬁcacy. According to Prins et al. (1993) the once daily dosing
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dosing. Moreover, Beucaire et al. (1991), Giamarellou et al.
(1991) and Watling and Dasta (1993) have demonstrated equal
clinical and bacteriological efﬁcacy with once daily dosing of
aminoglycosides compared to those with conventional dosing.
On the contrary, Raz et al. (1995) reported that clinical cure
rate was signiﬁcantly higher in ODD group, whereas microbi-
ological cure rate was insigniﬁcantly better in ODD group.
No statistically signiﬁcant difference was found between the
two dosing regimens concerning incidence of nephrotoxicity in
both aminoglycoside groups. A statistically insigniﬁcant
impairment of renal function was observed in four out of 23
patients (17.4%) in the ODD subgroup, and in four of 26 pa-
tients (15.4%) in the MDD subgroup (P-value = 0.85). Our
results were in agreement with Nordstrom et al. (1990) and
Trenika et al. (2005) who reported that once daily aminoglyco-
side administration has a similar adverse effect proﬁle when
compared to multiple daily dosing. Also, Jikoo et al. (1996)
found that ODD and pharmacokinetic dosing regimens of gen-
tamicin had equal toxicity. In addition, in a large study with
amikacin, where once daily administration of amikacin
(20 mg/kg) was compared with 8-hourly administration
(6.5 mg/kg every 8 h), the incidence of nephrotoxicity as indi-
cated by a rise in serum creatinine of at least 45 lmol/l was
not different between the two regimens (EORTC, 1993).
In contrast to our results, Bartal et al. (2003) reported a sta-
tistically signiﬁcant lower incidence of nephrotoxicity of ami-
noglycosides in the pharmacokinetic dosing group than in
the ODD group. Also, Prins et al. (1993) in a study of 123 pa-
tients with serious infections found that gentamicin was less
nephrotoxic when administered once daily than when it was gi-
ven 8 hourly. Similar to the study just described, Murry et al.
(1999) in a study on aminoglycosides, showed that the once
daily dosing regimen statistically signiﬁcantly reduces the risk
of nephrotoxicity compared to individualized traditional
dosing.
As was reported by Maire et al. (2000) the controversy in
the results of the different studies mentioned might be attrib-
uted to the fact that any advantage of once daily dosing regi-
men regarding nephrotoxicity is rendered less evident when
treatment has been prolonged (i.e. more than 7 days). In
our study, the mean duration of treatment in the ODD and
the MDD subgroups were (10.42 ± 7.83 days and 6.1 ±
2.33 days, respectively, in the amikacin group), and (7.9 ±
2.9 days and 6.25 ± 2.53 days, respectively, in the gentamicin
group). Duration of treatment in the ODD regimen was com-
parable in patients who had nephrotoxicity and those who did
not (5 ± 0.816 days versus 10.47 ± 6.65 days, respectively,
P-value = 0.06). This is in agreement with Jikoo et al. (1996)
who found that durations of aminoglycoside therapy were
not statistically signiﬁcantly different between patients who
developed nephrotoxicity and those who did not in the ODD
group.
Duration of treatment in the MDD regimen was statisti-
cally signiﬁcantly higher in patients who had nephrotoxicity
than those who did not (8.75 ± 3.3 days versus 5.73 ±
2.03 days, respectively, P-value = 0.02). In accordance with
these results, Prins et al. (1993) found that patients who devel-
oped nephrotoxicity had been treated longer with gentamicin
than patients who did not. Also, Eltahawy and Bahnassy
(1996) and Nicolau et al. (1995) reported that duration of ther-
apy was statistically signiﬁcantly associated with aminoglyco-side nephrotoxicity. The latter two studies, however did not
evaluate the dosing strategies in critically ill patients in partic-
ular. In amikacin ODD or MDD subgroups, the mean peak or
trough levels were statistically insigniﬁcantly different in pa-
tients who showed nephrotoxicity and those who did not.
Our results are in accordance with Prins et al. (1993) who
reported that the mean steady state peak levels were compara-
ble in patients who developed nephrotoxicity and those who
did not in either ODD or MDD subgroup, moreover, they re-
ported that the trough levels were higher in patients who devel-
oped nephrotoxicity in the ODD and MDD subgroups. Also,
according to Nicolau et al. (1995) aminoglycosides toxicity
does not seem to be associated with high peak concentrations.
However, when our patients were sub-divided according to
their serum peak concentrations into those below 35 mg/l and
those above 35 mg/l, our results showed that patients with
peak levels of more than 35 lg/ml exhibited higher incidence
of nephrotoxicity occurrence compared to those with peak lev-
els less than 35 lg/ml. This is in accordance with Jikoo et al.
(1996) study on elderly patients with suspected or conﬁrmed
infections who found that high serum peak levels were associ-
ated with higher incidence of nephrotoxicity in the ODD
group. The mean peak and trough concentrations were compa-
rable in patients who showed nephrotoxicity and those who
did not in gentamicin MDD subgroup. This is in agreement
with that obtained by Jikoo et al. (1996). Also our data showed
that 8.3% of patients who had serum gentamicin trough levels
62 lg/ml exhibited laboratory evidence of nephrotoxicity ver-
sus 28.6% of patients with serum gentamicin trough levels
>2 lg/ml although this was statistically insigniﬁcant. This is
in accordance with several studies suggesting that the incidence
of toxicity increases when trough values were more than 2 mg/l
for gentamicin (Barza et al., 1975; Dahlgren et al., 1975;
Jackson and Arcieri, 1971). In case of both regimens combined
of amikacin or gentamicin groups, the mean AUC at steady
state was not statistically signiﬁcantly different in patients
who showed evidence of nephrotoxicity and those who did
not. This is in disagreement with Rybak et al. (1999) who
reported a statistically signiﬁcant relation between high AUC
and increasing incidence of nephrotoxicity.
The statistically insigniﬁcant effect of high trough concen-
trations in either gentamicin or amikacin groups on increasing
incidence of nephrotoxicity could be attributed to the fact that,
in most studies, aminoglycoside doses were not altered in rela-
tion to plasma concentrations. In this study doses were adjusted
when trough concentrations were >2 mg/l in case of gentami-
cin or >5 mg/l in case of amikacin. So the patients in either the
ODD or MDD subgroups never experienced prolonged high
trough concentrations. The mean creatinine clearance of pa-
tients at the start of aminoglycosides treatment was statistically
non-signiﬁcantly different in patients who showed nephrotoxi-
city and those who did not, whether in the ODD or MDD reg-
imens (P-value = 0.316 and 0.375, respectively). Similar to our
results, Prins et al. (1993) in a study on gentamicin found that
patients who developed nephrotoxicity had a statistically insig-
niﬁcant lower creatinine clearance at the start of therapy in
either ODD or MDD regimens, P-value = 0.08 and 0.14,
respectively. Also, Jikoo et al. (1996) found that the mean ini-
tial serum creatinine of aminoglycosides were not statistically
signiﬁcantly different between patients who developed nephro-
toxicity and those who did not in each group. Our results
showed that there were no statistically signiﬁcant difference
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and those who did not in each of the ODD or MDD regimens.
According to Jikoo et al. (1996) age of patients was statistically
non-signiﬁcantly different between patients who developed
nephrotoxicity and those who did not in the ODD or the phar-
macokinetic dosing group. Other studies, however, reported
advanced age as one of the risk factors of aminoglycosides
nephrotoxicity (Humes, 1997; Zaske et al., 1986).
Our data showed that the time of taking once daily
gentamicin or amikacin in the rest period (midnight to
7:30 am) had no impact on nephrotoxicity of gentamicin or
amikacin (P-value > 0.05). On the other hand, a report from
a non-randomized, unblinded study showed a higher incidence
of nephrotoxicity when aminoglycosides were administered
during the rest period (Prins et al., 1997). The previous study
attributed the results to the fact that glomerular ﬁltration rates
are lower in humans during the rest period. Also, several stud-
ies showed that maximum renal toxicity was observed when
aminoglycosides were injected in the middle of the rest period
of the experimental animals, while lower toxicity was found
when they were treated in the middle of the activity period
(Hosokawa et al., 1993; Pariat et al., 1984, 1988). Unfortu-
nately, most studies evaluating the once daily dosing in
humans did not take into account the time of injections of
these antibiotics throughout the day.5. Conclusions
Our data indicate that the once daily dosing regimen is
preferred in critically ill patients to individualized multiple
daily dosing as shown by comparable efﬁcacy, nephrotoxicity
and lesser need for therapeutic drug monitoring and frequent
dose adjustments required in the individualized multiple daily
dosing regimen. Also, we speculate that further clinical trials
are required on a larger scale of patients to investigate the role
of administration time of once daily dosing regimen of
aminoglycosides on decreasing incidence of nephrotoxicity.Conﬂict of interest
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